EGCG Improves Acne by Modulating Molecular Targets
キーワード
概要
説明
Acne vulgaris is one of the most prevalent skin disorders of sebaceous follicles, affecting more than 85% of adolescents in United States. Acne can persist throughout the adulthood, and even a mild form of acne might progress to permanent scarring on the face, chest and back, thereby causing significant physical and psychosocial morbidities. Acne is a multifactorial disease of which etiology has not been fully elucidated, although considerable progress has been made in understanding its pathogenesis during last decade. The major pathogenic features of acne include abnormal ductal keratinization, sebum overproduction, Propionibacterium acnes, and inflammation. Common acne medications such as topical retinoids, antibiotics and isotretinoin are associated with irritation and incomplete responses, increased bacterial resistance or untoward side events, respectively. Thus there is a continuing need for a novel, effective agent targeting different aspects of acne pathogenesis, with minimal side effects.
In the recent decade, epigallocatechin-3-gallate (EGCG), the major polyphenolic constituent in green tea, has attracted much interest on account of its potent anti-carcinogenic, anti-inflammatory, anti-proliferative, and antimicrobial activities. Preclinical, observational, and clinical trial data have indicated that EGCG can inhibit tumor initiation, promotion, progression, and angiogenesis. EGCG also suppresses neutrophil chemotaxis, and has been suggested to improve many diseases that have inflammatory components such as diabetes, kidney injuries, arthritis, allergies, dental caries, cardiovascular, gastrointestinal, and neurodegenerative diseases. In skin, EGCG has been investigated mainly in light of antioxidative, immunopotentiating and anticarcinogenic properties against chemicals or ultraviolet irradiation. Moreover, EGCG has lipid-lowering and antiandrogenic properties, and can downregulate peroxisome proliferator-activated receptor-γ expression. Based on these observations, it can be inferred that EGCG might be effective in the treatment of acne.
日付
| 最終確認済み: | 08/31/2012 |
| 最初に提出された: | 07/22/2010 |
| 提出された推定登録数: | 09/12/2012 |
| 最初の投稿: | 09/18/2012 |
| 最終更新が送信されました: | 09/12/2012 |
| 最終更新日: | 09/18/2012 |
| 実際の研究開始日: | 06/30/2005 |
| 一次完了予定日: | 05/31/2006 |
| 研究完了予定日: | 05/31/2006 |
状態または病気
介入/治療
Other: topical EGCG application on acne
段階
アームグループ
| 腕 | 介入/治療 |
|---|---|
| Active Comparator: Topical EGCG 1% Seventeen subjects were designated to use 1% EGCG .Since baseline visits, affected areas of randomly allocated half sides were treated with 1% solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol). | |
| Experimental: topical EGCG 5% Eighteen subjects were designated to use 5% EGCG, to evaluate a dose-response relationship. Since baseline visits, affected areas of randomly allocated half sides were treated with 5% EGCG solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol). |
適格基準
| 研究の対象となる年齢 | 15 Years に 15 Years |
| 研究に適格な性別 | All |
| 健康なボランティアを受け入れる | はい |
| 基準 | Inclusion Criteria: - age of at least 15 years - clinical diagnosis of mild to moderate acne vulgaris Exclusion Criteria: - known pregnancy or lactation - any medical illness that might influence the results of the study, - a previous history of oral acne medication or surgical procedures including laser treatment within 6 month and topical medication within 4 weeks of study enrollment. |
結果
主な結果の測定
1. Assessment of acne severity [8 week after baseline]
二次的な結果の測定
1. 2-mm punch biopsy of acne lesion on the EGCG-treated sides [8 week after baseline]
2. Standardized clinical photographs [8 week after baseline]
